The Effect of Different Doses of Ellagic Acid on the Serum Lipid Profile and Total Antioxidant of Rat

Year 2017, Volume: 28 Issue: 3, 127 - 130, 20.12.2017

Songül Akkuş Yeter Değer

Abstract

This study was planned to  determine in which dose of ellagic acid  it shows the optimum effect on lipid, lipoprotein and total antioxidant capacity. For this purpose, 40 male rats (Wistar-albino) weighing 200- 250 g were used. Control, group 1 (EA 3 mg/kg), group 2 (EA 10 mg/kg), group 3 (EA 12 mg/kg) and group 4 (EA 20 mg /kg) were designated, each containing 8 rats.  Following orally application ofellagic acid  (EA) every other day for eight weeks, from the blood samples taken; the measurement of triglyceride, cholesterol, LDL and HDL were determined by modular auto-analyzer using commercial kit. VLDL levels were calculated by formula. The total antioxidant capacity (TAS) was measured through spectrophotometer using the commercial kit. When compared with the control group, it was found that while TAS, triglyceride, HDL and VLDL levels were increased, LDL and cholesterol levels were decreased in the all EA applied groups. These changes weren’t important statistically (P˃0.05). Consequently, with regard to the data acquired in this study, it is recommended that in further research, the protective dose of ellagic acid is higher than 20 mg/kg/day and prolonged use

Keywords

Ellagic acid, Rat, HDL, LDL, Triglyceride, Cholesterol, TAS

Farklı Doz Ellajik Asitin Rat Serum Lipit Profili ve Total Antioksidan Üzerine Etkisi

Abstract

Bu çalışma, ellajik asitin, lipit, lipoprotein ve total antioksidan kapasite üzerine optimum etkiyi hangi dozda gösterdiğini tespit etmek amacıyla planlandı. Bu amaçla 40 adet,  200-250 gr ağırlığında erkek rat (Wistar- albino) kullanıldı. Kontrol, 1. grup (EA 3 mg/kg), 2. grup (EA 10 mg/kg), 3. grup (EA 12 mg/kg)  ve 4. grup (EA 20 mg/kg) olmak üzere her biri 8 rattan oluşan 5 grup oluşturuldu. Sekiz hafta boyunca, gün aşırı olarak ellajik asitin (EA) oral olarak uygulanmasını takiben, alınan kan örneklerinde, trigliserit, kolesterol, HDL ve LDL ölçümleri ticari kit kullanılarak modüler oto-anlizör cihazında yapıldı. VLDL düzeyleri formülle hesaplandı.  TAS ölçümü ticari kit kullanılarak spektrofotometrede gerçekleştirildi. Kontrol grubu ile karşılaştırıldığında, EA verilen tüm gruplarda, TAS, HDL,  VLDL ve trigliserit seviyelerinin artarken,  LDL ve kolesterol seviyelerinin azaldığı tespit edildi. Bu değişiklikler istatistik olarak anlamlı değildi (p˃0.05). Sonuç olarak, bu çalışmada elde edilen verilere dayanarak, yapılacak çalışmalarda, ellajik asitin koruyucu dozunun 20 mg/kg/gün düzeyinden yüksek olması ve uzun süre kullanılması önerilir

Keywords

Ellajik asit, Rat, HDL, LDL, Trigliserid, Kolesterol, TAS

References

• Bozkurt Y, Fırat U, Atar M et al. (2012). The protective effect of ellagic acid against renalischemia-reperfusion injury in male rats. Kafkas Uni Vet Fak Derg, 18, 823-828. Böyük A, Önder A, Kapan M, Gümüş M, Fιrat U, Başaralι MK, Alp H (2011). Ellagic acid ameliorates lung injury after intestinal ischemia-reperfusion. Pharmacogn Mag, 27, 224–228. Brinton EA, Eisenberg S, Breslow JL (1991). Increased Apo A-I and Apo A-II fractional Catabolic rate in patients with low high density lipoprotein-cholesterol levels with or without hypertriglyceridemia. J Clin Investi, 87, 536-544. Chapman MJ, Ginsberg HN, Amarenco P et al. (2011). Triglyceride-rich lipoproteins and high-density lipoprotein cholesterol in patients at high risk of cardiovascular disease: evidence and guidance for management. Eur Heart, 32, 1345-1361. Chung KT, Wong TY, Wei Cl, Huang YW, Lin Y (1998). Tannins and human health: a Review. Crit Rev Food Sci Nutr, 38, 421-464. Clifford MN, Scalbert A (2000). Ellagitannins-nature, occurrence and dietary burden. J Sci Food Agric, 80, 1118-1125. Çelik S, Ökkeş Y (1996). The effects of dietary vitamin E on serum lipids and lipid peroxidation in diabetic rats. Turk J biol, 23, 39-46. Çeribaşı AO, Türk G, Sönmez M, Sakin F, Ateşşahin A (2010). Toxic effect of cyclophosphamide on sperm morphology, testicular histology and blood oxidant-antioxidant balance, and protective roles of lycopene and ellagic acid. Basic Clin Pharmacol Toxicol, 107, 730-736. Devipriya N, Sudheer AR, Menon VP (2007). Dose-response effect of ellagic acid on circulatory antioxidants and lipids during alcohol-induced toxicity in experimental rats. Fun Clin Pharmacol, 21, 621–630. Dönmez T (2006). Fındık ve Cevizin Sıçanlarda Serum Lipitleri, Aterosklerotik Lezyonlar ve Prooksidan-Antioksidan Denge Üzerine Etkisi. İstanbul Üniversitesi, Sağlık Bilimleri Enstitüsü Yüksek Lisans Tezi. Erel O (2004). A novel automated method to measure total antioxidant response against potent free radical reactions. Clin Biochem, 37, 112-119. Festa F, Aglitti T, Duranti G, Ricordy R, Perticone P, Cozzi R (2001). Strong antioxidant activity of ellagic acid in mammalian cells in vitro revealed by the comet assay. Anticancer Res, 21, 3903-3908. Ghiselli A, Serafini M, Natella F, Scaccini C (2000). Total antioxidant capacity as a tool to ases redox status, critical review and experimental data. Free Radic Biol Med, 29, 1106-1114. Gündüz H, Mert N (1997). Farklı ırklardaki ithal etçi koyunlarda serum lipoprotein düzeyleri. YYÜ Vet Fak Derg, 8, 25-27. Kanchana G, Malini P, Shyni WJ (2011). Membrane bound enzymes and lipid lowering effect of ellagic acid on normal and streptozotocin induced diabetic in albino wistar rats. J Pharm Res, 4, 1461-1463. Karagül H, Altıntaş A, Fidancı UR, Sel T (2000). Klinik Biyokimya. Medisan Yayınevi, Ankara. Khanduja KL, Gandhi RK, Pathania V, Syal N (1999). Prevention of nitrosodiethylamine- induced lung tumorigenesis by ellagic acid and quercetin in mice. Food Chem Toxicol, 37, 313-318. Lee J, Talcott ST (2002). Ellagic acid and ellagitannins affect on sedimentation in muscadine juice and wine. J Agric Food Chem, 50, 3971-3976. Lino T, Nakahara K, Miki W (2001). Less damaging effect of whisky in rat stomachs in comparison with pure ethanol. Role of ellagic acid, the nonalcoholic component. Digestion, 64, 214-221. MacKinnon KL, Molnar Z, Lowe D, Watson ID, Shearer E (1999). Measures of total free radical activity in critically ill patients. Clin Biochem, 32, 263-268. Meyer AS, Heinonen M, Edwin N (1998). Antioxidant interactions of catechin, cyanidin, cafeic acid, quercetin, and ellagic acid on human LDL oxidation. Food Chem, 61, 71-75. Molina MF, Sanchez-Reus I, Iglesias I, Benedi J (2003). Quercetin, a flavonoid antioxidant, prevent and protects against ethanol-induced oxidative stres in mouse liver. Biol Pharm Bull, 26, 1398-1402. Özkaya A (2007). Oksidatif Strese Maruz Kalan Ratların Bazı Biyokimyasal Parametrelerine Hesperetin ve Ellajik Asidin Etkisi. Fırat Üniversitesi, Fen Bilimleri Enstitüsü, Doktora Tezi. Panchal SK, Ward L, Brown L (2013). Ellagic acid attenuates high-carbohydrate, high-fat diet-induced metabolic syndrome in rats. Eur J Nutr,52, 559–568. Rehman MU, Tahir M, Ali F, Qamar W, Lateef A, Khan R, Quaiyoom A, Oday-O- Hamiza, Sultana S (2012). Cyclophosphamide-induced nephrotoxicity, genotoxicity, and damage in kidney genomic DNA of Swiss albino mice: the protective effect of ellagic acid. Mol Cell Biochem, 365, 119-127. Rodrigo R, Rivera G, Orellana M, Araya J, Bosco C (2002). Rat kidney antioxidant response to long-term exposure to flavonol rich red wine. Life Sci, 71, 2881-2889. Serafini M, Del Rio D (2004). Understanding the association between dietary antioxidants, redox status and disease: is the total antioxidant capacity the right tool? Redox Rep, 9, 145-152. Solon S, Lopes L, Teixeira de Sousa P Jr, Schmeda-Hirschmann G (2000). Free radical scavenging activity of Lafoensia pacari. J Ethnopharmacol, 72, 173-178. Stoner G D, Mukhtar H (995). Polyphenols as cancer chemopreventive agent. J Cell Biochem Suppl, 22, 169-180. Yoshimura Y, Nishii S, Zaima N, Moriyama T, Kawamura Y (2013). Ellagic acid improves hepatic steatosis and serum lipid composition through reduction of serum resistin levels and transcriptional activation of hepatic parpa in obese, diabetic KK-Ay mice. Biochem Biophys Res Commun, 434, 486–491.